Tsiproteron

Ципротерон Drug photo

The description is actual on 21.07.2016

  • Latin name: Cyproterone
  • ATH code: G03HA01
  • Active ingredient: Tsiproterona acetate (Cyproterone acetate)
  • Producer: Pharmachemie (Netherlands)

Structure

In 1 tablet of a tsiproteron of acetate of 50 mg. Potato starch, monohydrate of lactose, krospovidon, hydroxypropyl cellulose, sodium lauryl sulfate, talc, silicon dioxide, magnesium stearate as excipients.

Release form

Tablets No. 50.

Pharmacological action

Anti-androgenic.

Pharmacodynamics and pharmacokinetics

Pharmacodynamics

Synthetic antiandrogennny drug which active agent contacts receptors of men's hormones (androgens) in bodies that causes decrease in their activity. Completely eliminates or reduces action of androgens by a prostate.

At men decrease in sexual desire of function of seed plants which disappear after the end of treatment is noted. At women growth of hair in the person and an androgenic hair loss, excessive sebaceous secretion decreases, formation of eels stops. Increases the level of endorphines, reduces negative effect on them of androgens that positively affects an emotional state and sexual function. Drug is effective at girls at premature puberty.

The combination tsiproteron + ethinylestradiol is a part of monophase contraceptive drugs (Bellune-35, Diane-35, Erika-35, Hly) with anti-androgenic activity. The first component reduces an androgenization at women and, besides, oppresses secretion of gonadotropic hormones therefore brakes an ovulation and has contraceptive effect. Ethinylestradiol strengthens its influence on an ovulation, promotes increase of viscosity of slime in a neck and provides lasting contraceptive effect.

Pharmacokinetics

It is completely soaked up, biotransformirutsya in a liver, and the maximum concentration in serum is defined in 3 hours. Contacts blood proteins for 96%. It is removed by metabolites with bile and urine. An elimination half-life — 44 hours.

Indications to use

  • the prostate cancer (metastasizing, inoperable);
  • correction of deviations of a sexual behavior at men (for the purpose of decrease in sexual activity);
  • hirsutism and acne;
  • androgenization at women;
  • alopecia of androgenic genesis;
  • premature puberty (at children).

Contraindications

Side effects

  • abdominal pains;
  • increased fatigue, apathy;
  • nausea;
  • xeroderma;
  • muscular weakness;
  • depression or concern;
  • change of body weight;
  • gynecomastia at men;
  • suppression of a spermatogenesis;
  • increase in mammary glands at women;
  • decrease in a libido;
  • cyclic bleedings (in a postmenopause);
  • disturbances of a menstrual cycle.

Tsiproteron, application instruction (Way and dosage)

Tsiproteron Teva is applied inside with enough water.

At a prostate cancer — 200-300 mg a day in 2-3 receptions, are long.

For suppression of sexual activity — 2 tablets twice a day, several weeks with transition to a maintenance dose — 50 mg twice a day. Cancel drug gradually.

In childbearing age to women appoint 100 mg of times a day from the first to the 10th day of a cycle, it is at the same time necessary to accept contraceptives and to use barrier contraceptives. Repeated 10 day courses begin in 4 weeks. On reaching effect the dose is reduced to 25 mg a day. In an initiation of treatment pregnancy needs to be excluded. In a postmenopause 25-50 mg 21 days with the subsequent break in a week are applied.

Treatment is carried out under control of function of a liver, level of glucose and blood tests. At emergence of a hepatotoxic treatment is cancelled. At a diabetes mellitus sugar level is often controlled. At epilepsy, a porphyria, an arterial hypertension, at an otosclerosis the risk of side reactions increases. At having alcoholism use of drug it is inefficient.

Overdose

Drug has very much a hypotoxicity therefore even at accidental reception of a large number of tablets of intoxication it is not noted. It is necessary to cause vomiting and to apply symptomatic therapy according to indications.

Interaction

Alcohol reduces effect of drug. At use with contraceptives the risk of a thromboembolism increases.

Terms of sale

It is released according to the recipe.

Storage conditions

Temperature is up to 25 °C.

Period of validity

5 years.

Tsiproteron's analogs

Coincidence on the ATH code of the 4th level:

    Androkur, Androkur Depo.

    About Tsiproterona

    At increase of products of androgens at women signs of defenemination and even a masculinization are noted. The "erased" forms of a giperandrogeniya are the reason of infertility, anovulation, an amenorrhea, not incubation of pregnancy, a uterus hypoplasia.

    External manifestations of a giperandrogeniya are also unpleasant for the woman — fat seborrhea, an alopecia, an acne, a hirsutism of different degree of manifestation. At such states this drug to women is appointed and at some diseases at men. In clinical practice it is considered the most effective and safe.

    Judging by responses, it is the most frequent in gynecologic practice, at easy forms of a hirsutism Diane-35 combining two active agents (see above) was applied and it was appointed within 9 - 12 months. At an acne and an alopecia the effect was noted quicker — in 6 months.

    • "… Drug obviously suspended a hair loss and there was obvious growth new, but I hard transferred its reception — weight in right hypochondrium, an increase in weight, decrease in a libido".
    • "… Accepted DIANE-35 1 year – as a result a smart head of hear".

    At the expressed androgenization the effect was practically absent and to treatment a tsiproterona acetate in the form of drug Androkur or Tsiproteron Teva was in addition appointed. Such combination therapy was more effective. This drug was accepted by also some women at a polycystosis of ovaries.

    Zdravzona

    • Tsiproteron-Teva of 50 mg No. 50 tabletkiteva Pharmaceutical
    to show still
    Section: Hormonal
    in more detail

    Education: Graduated from Sverdlovsk medical school (1968 - 1971) as "Paramedic". Graduated from the Donetsk medical institute (1975 - 1981) as "An epidemiologist, a hygienist". Passed postgraduate study in the Central scientific research institute of epidemiology Moscow (1986 - 1989). An academic degree – the candidate of medical sciences (degree is awarded in 1989, protection – the Central scientific research institute of epidemiology Moscow). Numerous advanced training courses are studied in epidemiology and infectious diseases.

    Experience: Work as the manager of department of disinfection and sterilization of 1981 - 1992. Work as the manager of department of especially dangerous infections of 1992 - 2010. Teaching activity at Medical institute 2010 - 2013.

    PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Tsiproteron surely consult with the attending physician.